Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Pharmacol Ther. Sep 5, 2025; 16(3): 108190
Published online Sep 5, 2025. doi: 10.4292/wjgpt.v16.i3.108190
Published online Sep 5, 2025. doi: 10.4292/wjgpt.v16.i3.108190
Therapeutic and preventive treatment on outcomes of hepatitis B virus induced chronic liver disease with a cost-effectiveness analysis
Wei Zhu, Shanghai Xi Rong Information Science and Technology Company Limited, National Science and Technology Park, School of Life Sciences and Technology, Tongji University, Shanghai 200092, China
Author contributions: Zhu W designed the study, wrote the whole manuscript, and conducted all the figure and table, read and approved the final version of the manuscript to be published.
Supported by Natural Science Foundation of Shanghai, No. 17ZR1431400.
Conflict-of-interest statement: The author declares no relevant conflicts of interest for this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Wei Zhu, PhD, Post Doctoral Researcher, Shanghai Xi Rong Infor
Received: April 8, 2025
Revised: May 6, 2025
Accepted: July 7, 2025
Published online: September 5, 2025
Processing time: 149 Days and 18.5 Hours
Revised: May 6, 2025
Accepted: July 7, 2025
Published online: September 5, 2025
Processing time: 149 Days and 18.5 Hours
Core Tip
Core Tip: Hepatitis B virus (HBV) infection remains the major obstacle in the management of chronic liver disease worldwide, despite vaccination and anti-viral therapy. The life cycle of HBV replication in hepatocytes has a critical role in the escape of virus under the management strategy. It is important to summarize the associated factors between the host and virus in the development of HBV-mediated chronic progression using a cost-effectiveness analysis. This mini-review highlights both vaccination and anti-viral therapy interruption of the associated stages of the HBV life cycle as well as the corresponding cost-effectiveness methods applied to evaluate the diagnostic strategies, vaccination and treatment in HBV management.